Mersana Therapeutics reports Q4 EPS (11c), consensus (17c)
Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...
Morningstar11d
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
Wedbush Predicts Weaker Earnings for Mersana Therapeutics
Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...
Analysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Revelation Biosciences (REVB)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...
Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at Wedbush
Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report ...
manilatimes17d
Mersana Therapeutics to Present at Upcoming Investor Conferences
Archived replays will be available for approximately 90 days following the events. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug ...